Metabolism:肥胖是代谢相关脂肪肝患者发生更严重COVID-19的危险因素

2020-04-20 MedSci原创 MedSci原创

与无MAFLD的患者相比,MAFLD患者伴有肥胖发生严重COVID-19的风险更高。

代谢相关性脂肪肝疾病(MAFLD)患者多有肥胖,并伴有其它代谢危险因素,这些可能加重呼吸系统疾病和2019冠状病毒病(COVID-19)的严重程度。近日,代谢性疾病领域权威杂志Metabolism-Clinical and Experimental上发表了一篇研究文章,这项研究旨在调查MAFLD与COVID-19严重程度之间的关联。

研究人员连续招募了来自中国温州三家医院的214名经实验室检查确诊的COVID-19患者,年龄在18至75岁之间。最终分析纳入了66例MAFLD患者。通过口咽拭子标本的高通量测序或实时逆转录酶-聚合酶链反应测定来诊断COVID-19。在住院期间评估了COVID-19患者的严重程度,并根据当前的治疗指南将其分为严重和非严重病例。研究人员通过计算机断层扫描对所有患者进行脂肪肝筛查,随后根据最新的共识诊断标准判断有无MAFLD。肥胖定义为BMI>25kg/m2

MAFLD患者肥胖与严重COVID-19疾病风险增加6〜3倍相关(未调整OR为5.77,95%CI为1.19–27.91,p=0.029)。值得注意的是,即使在调整了年龄、性别、吸烟、糖尿病、高血压和血脂异常后,肥胖与COVID-19严重程度的相关性仍然很显著(调整后的OR为6.32,95%CI为1.16–34.54,p=0.033)。

由此可见,与无MAFLD的患者相比,MAFLD患者伴有肥胖发生严重COVID-19的风险更高。

原始出处:

Kenneth I. Zheng,et al.Obesity as a risk factor for greater severity of COVID-19 in patients with metabolic associated fatty liver disease.Metabolism-Clinical and Experimental.20120.https://www.metabolismjournal.com/article/S0026-0495(20)30108-6/fulltext

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1888135, encodeId=5abc18881351a, content=<a href='/topic/show?id=d56611584ec' target=_blank style='color:#2F92EE;'>#Meta#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11584, encryptionId=d56611584ec, topicName=Meta)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Fri Jan 15 00:45:51 CST 2021, time=2021-01-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1896641, encodeId=fe3f189664140, content=<a href='/topic/show?id=4a391158248' target=_blank style='color:#2F92EE;'>#MET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11582, encryptionId=4a391158248, topicName=MET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18fc139, createdName=一闲, createdTime=Wed Feb 03 16:45:51 CST 2021, time=2021-02-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1577223, encodeId=2d6415e722388, content=<a href='/topic/show?id=d86d1159e36' target=_blank style='color:#2F92EE;'>#Metabolism#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11597, encryptionId=d86d1159e36, topicName=Metabolism)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1a6516392333, createdName=1249859em43(暂无昵称), createdTime=Wed Apr 22 03:45:51 CST 2020, time=2020-04-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1598055, encodeId=d1ee15980556b, content=<a href='/topic/show?id=6c6f1e62c5' target=_blank style='color:#2F92EE;'>#ABO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1762, encryptionId=6c6f1e62c5, topicName=ABO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b6c918580135, createdName=闆锋旦, createdTime=Wed Apr 22 03:45:51 CST 2020, time=2020-04-22, status=1, ipAttribution=)]
    2021-01-15 zhaojie88
  2. [GetPortalCommentsPageByObjectIdResponse(id=1888135, encodeId=5abc18881351a, content=<a href='/topic/show?id=d56611584ec' target=_blank style='color:#2F92EE;'>#Meta#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11584, encryptionId=d56611584ec, topicName=Meta)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Fri Jan 15 00:45:51 CST 2021, time=2021-01-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1896641, encodeId=fe3f189664140, content=<a href='/topic/show?id=4a391158248' target=_blank style='color:#2F92EE;'>#MET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11582, encryptionId=4a391158248, topicName=MET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18fc139, createdName=一闲, createdTime=Wed Feb 03 16:45:51 CST 2021, time=2021-02-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1577223, encodeId=2d6415e722388, content=<a href='/topic/show?id=d86d1159e36' target=_blank style='color:#2F92EE;'>#Metabolism#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11597, encryptionId=d86d1159e36, topicName=Metabolism)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1a6516392333, createdName=1249859em43(暂无昵称), createdTime=Wed Apr 22 03:45:51 CST 2020, time=2020-04-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1598055, encodeId=d1ee15980556b, content=<a href='/topic/show?id=6c6f1e62c5' target=_blank style='color:#2F92EE;'>#ABO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1762, encryptionId=6c6f1e62c5, topicName=ABO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b6c918580135, createdName=闆锋旦, createdTime=Wed Apr 22 03:45:51 CST 2020, time=2020-04-22, status=1, ipAttribution=)]
    2021-02-03 一闲
  3. [GetPortalCommentsPageByObjectIdResponse(id=1888135, encodeId=5abc18881351a, content=<a href='/topic/show?id=d56611584ec' target=_blank style='color:#2F92EE;'>#Meta#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11584, encryptionId=d56611584ec, topicName=Meta)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Fri Jan 15 00:45:51 CST 2021, time=2021-01-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1896641, encodeId=fe3f189664140, content=<a href='/topic/show?id=4a391158248' target=_blank style='color:#2F92EE;'>#MET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11582, encryptionId=4a391158248, topicName=MET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18fc139, createdName=一闲, createdTime=Wed Feb 03 16:45:51 CST 2021, time=2021-02-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1577223, encodeId=2d6415e722388, content=<a href='/topic/show?id=d86d1159e36' target=_blank style='color:#2F92EE;'>#Metabolism#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11597, encryptionId=d86d1159e36, topicName=Metabolism)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1a6516392333, createdName=1249859em43(暂无昵称), createdTime=Wed Apr 22 03:45:51 CST 2020, time=2020-04-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1598055, encodeId=d1ee15980556b, content=<a href='/topic/show?id=6c6f1e62c5' target=_blank style='color:#2F92EE;'>#ABO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1762, encryptionId=6c6f1e62c5, topicName=ABO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b6c918580135, createdName=闆锋旦, createdTime=Wed Apr 22 03:45:51 CST 2020, time=2020-04-22, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1888135, encodeId=5abc18881351a, content=<a href='/topic/show?id=d56611584ec' target=_blank style='color:#2F92EE;'>#Meta#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11584, encryptionId=d56611584ec, topicName=Meta)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Fri Jan 15 00:45:51 CST 2021, time=2021-01-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1896641, encodeId=fe3f189664140, content=<a href='/topic/show?id=4a391158248' target=_blank style='color:#2F92EE;'>#MET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11582, encryptionId=4a391158248, topicName=MET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18fc139, createdName=一闲, createdTime=Wed Feb 03 16:45:51 CST 2021, time=2021-02-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1577223, encodeId=2d6415e722388, content=<a href='/topic/show?id=d86d1159e36' target=_blank style='color:#2F92EE;'>#Metabolism#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11597, encryptionId=d86d1159e36, topicName=Metabolism)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1a6516392333, createdName=1249859em43(暂无昵称), createdTime=Wed Apr 22 03:45:51 CST 2020, time=2020-04-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1598055, encodeId=d1ee15980556b, content=<a href='/topic/show?id=6c6f1e62c5' target=_blank style='color:#2F92EE;'>#ABO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1762, encryptionId=6c6f1e62c5, topicName=ABO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b6c918580135, createdName=闆锋旦, createdTime=Wed Apr 22 03:45:51 CST 2020, time=2020-04-22, status=1, ipAttribution=)]
    2020-04-22 闆锋旦

相关资讯

Stroke:瑞典研究称,青年变胖超十斤,老来中风危险增40%

近期发表在Stroke杂志的挪威奥斯陆缺血研究提示,健康人青年时期如果长胖,老年后中风和死亡的风险会显著增加,但中年时期增肥影响不大。

肥胖女性练普拉提身心受益!美国高血压杂志研究

肥胖不是好事!不仅形象不好,而且预示高血压和早期血管并发症的风险。

JAHA:Fontan循环年轻患者的身体成分

Fontan循环年轻患者身体成分的特征是骨骼肌质量下降,这与运动能力的峰值相关。尽管体重指数正常,但脂肪增加很常见。

Radiology:或许这才是靠谱体脂率测量的方法!

代谢综合征是与肥胖和异位脂肪分布是有相关性的。

Hypertension:IL-1受体拮抗剂可增加肥胖个体Ang(1-7)水平并降低血压

肥胖患者IL-1拮抗剂治疗4周后,Ang(1-7)水平升高,同时外周血管阻力降低。这些结果表明IL-1拮抗剂的降血压效应是通过调节Ang(1-7)来实现的。

Ann Rheum Dis:骨软骨界面的水平裂隙:肥胖相关性骨关节炎的新型病理特征

肥胖OA患者的关键病理特征是骨软骨界面的水平裂隙。肥胖与初次TKR的年轻化密切相关,这可能是水平裂隙引起的。